Adlai Nortye (NASDAQ:ANL) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Adlai Nortye (NASDAQ:ANL) in a research report report published on Monday morning,Benzinga reports. The firm currently has a $9.00 target price on the stock.

Adlai Nortye Stock Up 6.3 %

Shares of ANL stock opened at $3.02 on Monday. Adlai Nortye has a fifty-two week low of $1.85 and a fifty-two week high of $17.48. The stock’s fifty day moving average price is $2.15 and its two-hundred day moving average price is $4.61.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.